IMDx Enters into an Agreement with QIAGEN to Develop Molecular Tests

IMDx (privately held) announced today that it has entered into a multi-year development and license agreement with QIAGEN QGENQIA to design, develop and manufacture several undisclosed CE-marked and FDA cleared diagnostic tests for use on QIAGEN's flagship QIAsymphony RGQ automated platform. Financial terms have not been disclosed. The undisclosed assays being developed by IMDx are planned to be incorporated into QIAGEN's growing menu of molecular diagnostic assays and will be distributed by QIAGEN worldwide. QIAGEN has also retained the rights to assume manufacturing of the assays pursuant to volume considerations. IMDx's innovative